Tricida Inc

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week

Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020

New York, New York--(Newsfile Corp. - September 4, 2020) -  Rosen Law Firm, a global investor rights law firm, announces investigation of potential securities claims on behalf of shareholders of Tricida, Inc.

Rosen, A Leading Law Firm, Announces Investigation of Securities Claims Against Tricida, Inc. - TCDA

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces investigation of potential securities claims on behalf of shareholders of Tricida, Inc. (NASDAQ: TCDA) resulting from allegations that Tricida may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Announces Investigation of Securities Claims Against Tricida, Inc. – TCDA

NEW YORK, Aug. 27, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tricida, Inc.

TCDA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Tricida, Inc. Investors of Investigation and Encourages Investors to Contact the Firm

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q2 2020 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc.

Tricida to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on Wednesday, August 5, 2020

Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).

Tricida (TCDA) Plummets on Regulatory Update on Veverimer

The FDA has noted deficiencies in the application for approval of its only drug in development.

Here's Why Tricida Is Tanking 38.5% Today

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q1 2020 Results - Earnings Call Transcript

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q4 2019 Results - Earnings Call Transcript

Tricida is up nearly 100% since we recommended it in January 2019.

Tricida: There Is Further Upside

Tricida's (TCDA) CEO Gerrit Klaerner on Q3 2019 Results - Earnings Call Transcript

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q2 2019 Results - Earnings Call Transcript

NAPCO Security Technologies

Stifel Financial

Under Armour

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

4 Stocks Set to Pop on New Analyst Coverage

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q1 2019 Results - Earnings Call Transcript

It looks like the company found an easy solution to a big problem.

Here's What Drove Tricida 67% Higher in March

MAG Silver

Comscore Inc.

Even on a great day on Wall Street, these companies couldn't share in the good news.

Why MAG Silver, comScore, and Tricida Slumped Today

As of late, it has definitely been a great time to be an investor in Tricida.

Will Tricida Continue to Surge Higher?

Clinical trial results were a bit better than expected.

Here's Why Tricida's Soaring Today

After Tricida Inc. announced results from its chronic kidney disease (CKD) trial, its shares jumped on Thursday.

What’s Next for Tricida’s Chronic Kidney Disease Treatment

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on TRCA-301E Clinical Trial Results and Q4 2018 Results - Earnings Call Transcript

News for Tricida Inc Stock (TCDA)